Development and validation of a mass spectrometry based analytical method to quantify the ratios in hemagglutinin trimers in quadrivalent influenza nanoparticle vaccine - FluMos-v1

Asif Shajahan; Cindy X Cai; Jeremy Wolff; R Sylvie Yang; Vera B Ivleva; Daniel B Gowetski; Jason G D Gall; Q Paula Lei

doi:10.1039/d2ay01890j

Development and validation of a mass spectrometry based analytical method to quantify the ratios in hemagglutinin trimers in quadrivalent influenza nanoparticle vaccine - FluMos-v1

Anal Methods. 2023 Feb 16;15(7):896-900. doi: 10.1039/d2ay01890j.

Authors

Asif Shajahan¹, Cindy X Cai¹, Jeremy Wolff¹, R Sylvie Yang¹, Vera B Ivleva¹, Daniel B Gowetski¹, Jason G D Gall¹, Q Paula Lei¹

Affiliation

¹ Vaccine Production Program Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Gaithersburg, MD, USA. paula.lei@nih.gov.

PMID: 36723411
DOI: 10.1039/d2ay01890j

Abstract

A quadrivalent influenza nanoparticle vaccine (FluMos-v1) offers long-lasting protection against multiple influenza virus strains and is composed of four strains of hemagglutinin trimer (HAT) assembled around a pentamer core. Here we report an LC-MS/MS analytical development and validation method to measure the percentage of each HAT component in FluMos-v1.

Publication types

Research Support, N.I.H., Intramural

MeSH terms

Antibodies, Viral
Chromatography, Liquid
Hemagglutinin Glycoproteins, Influenza Virus / chemistry
Hemagglutinins
Humans
Influenza Vaccines* / chemistry
Influenza, Human* / prevention & control
Nanoparticles*
Tandem Mass Spectrometry

Substances

Influenza Vaccines
Hemagglutinins
Antibodies, Viral
Hemagglutinin Glycoproteins, Influenza Virus